Articles published by Centogene NV
 
    
   
    CENTOGENE Announces Voting Results of Extraordinary General Meeting
    
   December 04, 2024
   From Centogene NV
   Via GlobeNewswire
    
    
   
    CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
    
   November 13, 2024
   From Centogene NV
   Via GlobeNewswire
    
    
   
    CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
    
   September 25, 2024
   From Centogene NV
   Via GlobeNewswire
    
    
   
    CENTOGENE Receives Delisting Notice From Nasdaq
    
   August 07, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
    
   August 01, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
    
   June 20, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   From Centogene NV
   Via GlobeNewswire
    
    
   
    CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
    
   May 10, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Receives Nasdaq Non-Compliance Notice
    
   April 02, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
    
   
    CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
    
   February 29, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
    
   February 28, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Explores Strategic Alternatives
    
   February 28, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
    
   
    CENTOGENE Receives French Research Tax Credit Accreditation
    
   January 24, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
    
   
    CENTOGENE Announces Preliminary Full Year 2023 Revenue
    
   January 18, 2024
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Announces Voting Results of Extraordinary General Meeting
    
   December 19, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
    
   December 13, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
    
   November 28, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
    
   
    CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
    
   October 10, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Reports First Half 2023 Financial Results
    
   September 07, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
    
   
    CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
    
   September 01, 2023
   From Centogene NV
   Via GlobeNewswire
    Tickers
      CNTG
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.